• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Granules gets US FDA nod for OTC naproxen sodium and diphenhydramine hydrochloride tablets

expresspharmaSeptember 27, 2020

Tag: granules india , FDA , naproxen sodium , diphenhydramine hydrochloride tablets

Granules India announced that the US Food & Drug Administration (US FDA) has approved its abbreviated new drug application (ANDA) for naproxen sodium and diphenhydramine hydrochloride tablets, 220 mg/25 mg (OTC), generic equivalent of Aleve PM Tablets, 220 mg/25 mg, of Bayer HealthCare.

Naproxen sodium and diphenhydramine hydrochloride tablets are used for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.

Granules now has a total of 31 ANDA approvals from US FDA (29 final approvals and two tentative approvals).

Previous:Dr Reddy’s launches dexmedetomidine hydrochloride in 0.9% sodium chloride injection in US

Next:US FDA approves Zydus Cadila’s dimethyl fumarate DR capsules

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Granules gets US FDA nod for OTC naproxen sodium and diphenhydramine hydrochloride tablets | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Adriacin HCL (FDA)

Adriacin HCL (FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Ribavirin (FDA)

Ribavirin (FDA)
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Irinotecan (FDA)

Irinotecan (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Ivermectin (FDA)

Ivermectin (FDA)
Simvastatin (FDA)

Simvastatin (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service